title: Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience.
abstract: OBJECTIVE
  We report the clinical outcomes of 22 patients with primary intraocular lymphoma (PIOL) treated over a 15-year period.
  
  
  METHODS
  Patients with confirmed PIOL by central pathology review treated from 1994 to 2010 with isolated ocular (N=13) or central nervous system (CNS) plus ocular involvement (N=9) were included. Intraocular and CNS failure-free survival, relapse-free survival, and overall survival outcomes were analyzed.
  
  
  RESULTS
  Median follow-up was 29.0 (range, 10.2 to 96.4) months. Sixteen patients (9 with isolated ocular, 7 with ocular and CNS disease) received combined modality therapy (CMT) consisting of systemic chemotherapy (usually high-dose methotrexate based) and orbital +/- whole-brain radiation. Two patients were treated with chemotherapy and 4 with local ocular therapy alone. Among patients with isolated ocular versus CNS involvement, CNS failure-free survival was 79% versus 57%, and intraocular failures were 62% versus 78% at 24 months. Median relapse-free survival was 34.0 versus 21.3 months (P=0.368), and overall survival 43.4 versus 30.3 months (P=0.744), respectively. Three patients treated with CMT (2 with isolated ocular and 1 with CNS involvement) with >1-year follow-up alive at the time of analysis never relapsed, and one remains disease-free >4.5 years after treatment.
  
  
  CONCLUSIONS
  In this series of patients with PIOL+/- CNS disease, CNS and intraocular relapse were common. A trend toward better survival was seen among patients with isolated ocular presentation, and a limited number of long-term disease-free survivors seen after CMT.
authors.affiliation: Departments of *Radiation Oncology †Hematopathology ‡Ophthalmology ∥Lymphoma Medical Oncology, The University of Texas MD Anderson Cancer Center §Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX.
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Kim
authors.forename: Bouthaina S
authors.initials: BS
authors.lastname: Dabaja
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Medeiros
authors.forename: Stella
authors.initials: S
authors.lastname: Kim
authors.forename: Pamela
authors.initials: P
authors.lastname: Allen
authors.forename: Patricia
authors.initials: P
authors.lastname: Chevez-Barrios
authors.forename: Dan S
authors.initials: DS
authors.lastname: Gombos
authors.forename: Nathan
authors.initials: N
authors.lastname: Fowler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D064090:Intraocular Lymphoma / Q000401:mortality* / Q000628:therapy*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011878:Radiotherapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents